Menu

Biotechnology

Decades of experience supporting the biotechnology industry to develop breakthrough products and technologies

Crown Bioscience Enters Merger Agreement With JSR Corporation

Learn More

Cell Design Labs Sells to Gilead

Learn More

OnCore Biopharma Announces Merger Agreement with Tekmira Pharmaceuticals

Learn More

Immunocore Limited, developer of biologic drugs for immunotherapies, $320 million Series A financing

Learn More

FibroGen Closes Largest Biotech IPO in 12 Years

Learn More
Why Cooley
  • 900+ private and public biotechnology clients
  • Counsel to more than 50% of the companies on the NASDAQ Biotechnology Index
  • Services capabilities built specifically for biotechnology and life sciences companies
  • Team includes former biotech researchers, pharmaceutical marketing specialists, business consultants and in-house counsel at life sciences companies
  • Unparalleled access to the largest and most influential network of strategic investors
Read more
Group Contacts
Tom Coll Partner, San Diego
Sonya Erickson Partner, Seattle
Barbara Kosacz Partner, Palo Alto
Jeffrey Libson Partner
James Linfield Partner, Colorado
Nicola Maguire Partner, London
Yvan-Claude Pierre Partner, New York
Christian Plaza Partner, Reston
Marc Recht Partner, Boston
Michael Tuscan Partner in Charge - Washington, DC
John Wilkinson Partner, London
ViewHide related contacts


Error

Listing Returned 0 Results.

More

Related Practices & Industries
Life Sciences Emerging Companies Venture Capital Mergers & Acquisitions Capital Markets Life Sciences IP Litigation
ViewHide related news


Error

Listing Returned 0 Results.

More

ViewHide related events


Error

Listing Returned 0 Results.

More

Contact us

Back to top

© 2019 Cooley LLP and Cooley (UK) LLP. All rights reserved.

Cooley® is a registered service mark of Cooley LLP in the United States and European Union as well as certain other jurisdictions.